Influence of glucometric ‘dynamical’ variables on duodenal‐jejunal bypass liner (DJBL) anthropometric and metabolic outcomes

Colás, Ana Fanlo; Varela, Manuel; Mráz, Miloš; Novák, Daniel; Cuesta–Frau, David; Vigil, Luis; Benes, Marek; Pelikánová, Terezie; Haluzı́k, Martin; Burda, Václav; Vargas, Borja

doi:10.1002/dmrr.3287

Cited by 3 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies included seven randomized controlled trials (RCT), 18 observational studies, one combined observational and retrospective cohort study, one retrospective cohort study, and one retrospective case control study (Table 1). 6,7,10,14,23–46 Data from five studies reporting secondary analysis or long‐term data of patients from the included studies were added to our analysis to supplement outcome data at explant or in post‐explant follow‐up when not reported in the original included study 8,13,47–49 …”

Section: Resultsmentioning

confidence: 99%

Duodenal–jejunal bypass liners are superior to optimal medical management in ameliorating metabolic dysfunction: A systematic review and meta‐analysis

et al. 2023

View full text Add to dashboard Cite

Summary This systematic review and meta‐analysis evaluates metabolic and anthropometric outcomes of duodenal–jejunal bypass liners (DJBLs) compared to optimal medical management for the treatment of obesity and its associated metabolic complications. A systematic search of MEDLINE, Embase, Scopus, and Web of Science databases was conducted. Studies were reviewed and data were extracted following the PRISMA guidelines. The primary outcome was glycated hemoglobin (HbA1c) change at device explant with secondary outcomes including body mass index (BMI), weight, fasting plasma glucose (FPG), and adverse events. Twenty‐eight studies met inclusion criteria evaluating a total of 1229 patients undergoing DJBL treatment. When compared to medical management, DJBLs provided superior reductions in HbA1c (mean difference, MD −0.96%; 95% CI −1.43, −0.49; p < 0.0001), FPG (MD −1.76 mmol/L; 95% CI −2.80, −0.72; p = 0.0009), BMI (MD −2.80 kg/m2; 95% CI −4.18, −1.41; p < 0.0001), and weight (MD −5.45 kg; 95% CI −9.80, −1.09, p = 0.01). Post‐explant data reveals a gradual return to baseline status. Incidence of early device explant was 20.2%. Complications were resolved conservatively or with device explant without long‐term morbidity or mortality. We conclude that DJBLs provide significant metabolic and anthropometric improvements for patients with obesity. Uncertainty about the extent to which improvements are maintained after device removal may limit the use of DJBLs as a standalone treatment for obesity and associated metabolic complications.

show abstract

Section: Resultsmentioning

confidence: 99%

Duodenal–jejunal bypass liners are superior to optimal medical management in ameliorating metabolic dysfunction: A systematic review and meta‐analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

Efficacy and safety of duodenal–jejunal bypass liner for obesity and type 2 diabetes: A systematic review and meta‐analysis

Chen,

Feng,

Dong

et al. 2024

Obesity Reviews

View full text Add to dashboard Cite

SummaryThis study aimed to evaluate the efficacy and safety of duodenal–jejunal bypass liner (DJBL) for obesity and type 2 diabetes mellitus. A comprehensive search of electronic databases was conducted up to September 15, 2022. Thirty studies involving 1751 patients were included. At 12 months post‐implantation, the reduction in body mass index (BMI) was 4.8 kg/m2 (95% CI 4.1, 5.5), with an excess weight loss of 41.3% (95% CI 33.4%,49.2%) and a total weight loss of 13.1% (95% CI 10.1%, 16.0%). Significant decrease was observed in HbA1c and fasting glucose, with a standardized mean difference of − 0.72 (95% CI − 0.95, − 0.48) and − 0.62 (95% CI − 0.82, − 0.42), respectively. However, these improvements in weight loss and glycemic control were only partially sustained after explantation. In situ, DJBL significantly improves blood pressure and lipid levels. The pooled early removal rate was 19%, and the incidence of severe adverse events was 17%, including device migration (6%), gastrointestinal hemorrhage (4%), device obstruction (4%), and hepatic abscess (2%). DJBL offers significant improvement in weight loss and glycemic control, as well as cardiovascular parameters while in situ. Further studies are warranted to better understand the long‐term efficacy and safety of DJBL. The benefits of DJBL need to be carefully weighed against the risks in clinical decision‐making.

show abstract

The role of duodenal jejunal bypass liner in obesity treatment

Ülger¹,

Tayfur

Çakiroğlu³

et al. 2021

AIMSMEDS

View full text Add to dashboard Cite

<abstract> <p>Endoscopic bariatric procedures including Duedenal Jejunal Bypass Liner (DJBL) have become widespread in obesity treatment in recent years. The aim of this systematic review was to assess the role of DJBL in obesity treatment. A comprehensive search of several databases, including Cochrane Library, PubMed, and Web of Science was conducted to December 2020. Twenty-four clinical studies were assessed. According to the results, it is clear that DJBL provides effective weight reduction at 6–12 months and significant improvements in parameters associated with metabolic syndrome and cardiovascular disease. This technique also has potential to reduce comedications in patients with obesity and type 2 diabetes. Although these positive effects of DJBL are clear, its effect on liver, pancreatic functions, and inflammation markers are not clear yet. In addition, the overall and serious complication (gastrointestinal bleeds, pancreatitis, hepatic abscess, obstruction of the sleeve, biliary colic without cholecystitis and cholangitis) rate causing from the DJBL is very high. DJBL has not been approved by the Food and Drug Administration due to the frequency and severity of complications it causes. While it is certain that DJBL has significant effects on obesity and obesity related comorbidities, the safety aspect needs to be improved.</p> </abstract>

show abstract

Influence of glucometric ‘dynamical’ variables on duodenal‐jejunal bypass liner (DJBL) anthropometric and metabolic outcomes

Cited by 3 publications

References 71 publications

Duodenal–jejunal bypass liners are superior to optimal medical management in ameliorating metabolic dysfunction: A systematic review and meta‐analysis

Duodenal–jejunal bypass liners are superior to optimal medical management in ameliorating metabolic dysfunction: A systematic review and meta‐analysis

Efficacy and safety of duodenal–jejunal bypass liner for obesity and type 2 diabetes: A systematic review and meta‐analysis

The role of duodenal jejunal bypass liner in obesity treatment

Contact Info

Product

Resources

About